TOI Q1 revenue $104.4M (+10.3% YoY); net loss $19.6M vs $19.9M; reaffirms FY2025 guidance

Oncology Institute, Inc.

2025-Q1 EPS reported -$0.21 revenue$104,406,000

Revenue $104.4M, up 10.3% YoY from $94.7M; gross profit $17.2M, up 44.1%.
Net loss $19.6M ($0.21/share) vs $19.9M ($0.22) prior year; Adjusted EBITDA -$5.1M vs -$10.9M.
Pharmacy & Dispensary segment revenue $49.3M, gross profit >$9M, grew >20% YoY; FFS growth 9% QoQ.
Added >100,000 capitated lives in Q1; new contracts in FL, NV, CA; fully-delegated agreement started March 1 in FL.
Closed $16.5M private placement; exchanged $4.1M convertible notes for preferred stock & warrants; cash $39.7M.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001079973-25-000800
form_type: 8-K
ticker: TOI
cik: 0001799191
company_name: Oncology Institute, Inc.
filed_at: 2025-05-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:49.760362+00:00
generated_at: 2026-05-21T09:47:44.890599+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001079973-25-000800
json_url: https://secwatch.observer/filing/0001079973-25-000800.json
markdown_url: https://secwatch.observer/filing/0001079973-25-000800.md
text_url: https://secwatch.observer/filing/0001079973-25-000800.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1799191/000107997325000800/0001079973-25-000800-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1799191/000107997325000800/toi_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001079973-25-000800

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.